Clinical Trial Update: Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating whether adding Tenecteplase to alteplase (rt-PA) improves outcomes for proximal middle cerebral artery occlusion has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Tenecteplase (tenecteplase)
• alteplase (rt-PA) (alteplase)

Snippet

Sponsor: University Hospital Center of Martinique | Conditions: Nervous System Disorders, Cerebral Artery | Phase 2 | Status: WITHDRAWN